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Summary 
The B cell receptor for antigen (BCR) is a complex of membrane immunoglobulin (mIg) and 
at least two other proteins, Igor (mb-1) and Ig~ (B29). This complex promotes surface expression 
of the BCR and acts to transduce an activation signal. We have used a system of/~ heavy chain 
constructs transfected into murine B cell lines to probe structure-function relationships in the 
BCR complex. One mutant # chain, in which two polar transmembrane residues (TyrssT, Sersss) 
are replaced with valine, fails to associate with Igc~ and Ig~/and is incapable of transducing signals 
as a result of mlg cross-linking.  This mutant is expressed on the surface at high levels when 
transfected into a plasmacytoma line that lacks Igcr  whereas wild-type # is retained in this cell 
line in the endoplasmic reticulum. Pulse-chase and immunoprecipitation analyses indicate that 
the mutant is more rapidly released from calnexin than the wild-type #. Further, transfection 
of Iga into this Igor-negative cell line allows release of the/~ chain from calnexin and surface 
expression of the BCR. These results identify the transmembrane residues of/~ heavy chain that 
control binding to calnexin and Igor, and suggest that calnexin-dependent intracellular retention 
is an important control mechanism for expression  of the BCR complex. 
T 
he B cell receptor for antigen (BCR) 1 is a membrane- 
bound immunoglobulin (mIg), expressed on the surface 
of mature B cells as part of a complex of molecules.  This 
complex, which has  many features  in common with  the 
TCR-CD3 complex (1), includes Iga (the product of the 
mb-1 gene) and Igfl ~the product of the B29 gene). Both 
mb-1 and B29 have been cloned from T  cell-subtracted B 
cell libraries  (2-4).  Igor is a 32-kD phosphoprotein (5-7), 
and IgB exists as two differentially  processed proteins, one 
39 kD and one 37 kD, that form disulfide-linked dimers with 
Igor (8, 9).  Both Igor and IgB have structural homologies 
to CD3 chains (10). Igor and Ig~8 are noncovalently  associated 
with mIg, at least in part via polar interactions in the trans- 
membrane (TM) region of the mIg molecule (11, 12). The 
two functions of the BCR are internalization of bound an- 
tigen for subsequent presentation, and antigen-induced cel- 
lular activation. We and others have shown that transmis- 
sion of the TM activation signal is dependent on an intact 
BCR complex (11, 12), whereas the importance of Igc~ and 
1  Abbreviations used in this  paper: BCR, B cell receptor for antigen; DM, 
dodecyl maltoside; Endo-H, Endoglycosidase H; ER, endoplasmic retic- 
ulum; TM, transmembrane;  WT, wild-type mlgM; Y:F, Tyrss7 to Phe 
transmembrane mutant; YS:VV, Tyrssv/Sersss to Val/Val transmembrane 
mutant. 
Igfl for the antigen internalization and presentation function 
of the BCR is less clear (11, 13,  14). 
The fully assembled BCR complex is expressed on ma- 
ture, antigen responsive B cells but not on B cell progenitors 
or differentiated plasma cells, which are not antigen respon- 
sive. This developmentally regulated expression of the BCR 
is controlled by two main mechanisms. One is preferential 
transcription, first of the membrane-bound forms of heavy 
chains in mature B cells and later of the secreted forms in 
activated B cells and plasma cells. The other control mecha- 
nism is dependent on Igor, which is expressed only in pre-B 
and mature, surface Ig + B cells. This control of BCR sur- 
face expression was the first characterized  function of Igor, 
and again has analogies to surface expression of the TCR com- 
plex in T  cells (1). Thus, mlg transfected into either non- 
lymphoid or plasmacytoma cells, in which Igor is not syn- 
thesized,  is  retained  intracellularly  and  is  not  expressed 
efficiently on the plasma membrane (15-17). The site of in- 
tracellular retention is the endoplasmic reticulum (ER) (16-18), 
but the specific mechanism for mlg retention in the absence 
of Igol and how Igol promotes surface expression of mlg are 
not known. Expression of the BCR complex is a model for 
studying the biochemical mechanisms that control the ex- 
pression  of multimeric membrane receptors. 
We have created a number of human/z constructs with 
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mains (13), which we have used to define the structural re- 
quirements for the formation and function of the BCR com- 
plex (11). One such mutant, called YS:W, in which two polar 
transmembrane residues, Tyrs87 and Sersss, are replaced with 
valines, fails to associate with Igo~ and IgB and fails to signal 
upon antigen binding or to efl~dently present bound antigen. 
Despite this lack of association with the BCR complex, how- 
ever, the TM mutant/~ is expressed at levels comparable to 
wild-type (WT) #  or the endogenously produced Ig when 
transfected into a mouse mature B cell line A20 (13). Fur- 
thermore, unlike a mutation which deletes the cytoplasmic 
tail of mlg, thereby rendering the molecule phosphatidyl- 
inositol linked, the transmembrane mutant YS:W is expressed 
as an integral membrane protein (19). Thus, the YS:VV mu- 
tant seems to escape the normal control mechanism for the 
expression ofmlg on the B cell surface, in that it is expressed 
in the absence of the other molecules of the BCR complex. 
We have used these mlg constructs to analyze the mecha- 
nisms that control mlg expression,  by transfecting the mlg 
into a cell line that lacks Igor. Our results indicate that binding 
to the ER chaperone,  calnexin, is an important mechanism 
for retaining # heavy chains intracellularly, and one function 
of Igo~ may be to release heavy chains from calnexin. Such 
regulated release from intracellular retention may be a general 
mechanism for controlling surface expression  of multimeric 
receptor complexes. 
Materials and Methods 
Ig Constructs and Cell Lines.  The Ig constructs used in these 
studies have been described elsewhere (13). The WT # consists 
of a rearranged V-D-J from the mouse plasmacytoma $107 and 
human C# regions. The two mutants are Tyrss7/Sersss  to Val/Val 
(YS:VV) and Tyrss7 to Phe (Y:F). The functions of these mutants 
transfected into the mature B lymphoma line A20 have been de- 
scribed previously  (13). Transfectants  ofJ558L, a murine plasmacy- 
toma cell  line, were prepared similarly  by coelectroporating  the WT 
or mutant # constructs with the $107 g chain in a plasmid con- 
taining the neomycin  resistance gene. After transfection and sdec- 
tion in G418, the cells  were grown in bulk populations (representing 
a large number of separate transfection  events), and were also cloned 
by limiting dilution. No sorting to isolate higher surface expres- 
sion was employed.  To produce the WT/Igcx transfectant of  J558L, 
J558L WT cells were then further transfected with a vector con- 
taining the rob-1 gene (20, kindly provided by Dr. Michel Nus- 
senzwieg, The Rockefeller Universityj New York), which codes 
for Igc~, as well as the His resistance gene. Histidinol and G418 
resistant clones  were obtained  by limiting dilution. Again, no sorting 
to isolate higher surface expression was employed. 
Antibodies.  Affinity-purified  goat anti-human # and goat anti- 
human K  (Southern Biotechnology Associates, Birmingham, AL) 
and normal goat IgG (Cappel Laboratories, Durham,  NC) were 
coupled to CNBr-activated  Sepharose  CL4B (Sigma  Chemical Co., 
St. Louis, MO) for use in preclearing  or immunoprecipitation.  Anti- 
mouse calnexin antiserum is described elsewhere (21). Anti-Igc~ 
antiserum was the kind gift of  Dr. John Cambier (National Jewish 
Medical Center, Denver, CO). 
Western Blotting.  25  x  106 cell equivalents of each cell line 
were lysed with 1% dodecyl maltoside (DM; Anatrace; Maumee, 
OH) or 1% NP-40 (Sigma Chemical Co.) in lysis  buffer (150 mM 
NaC1, 10 mM Tris, pH 7.3, and 1 mM EDTA) in the presence 
of  protease  inhibitors  (PMSF, leupeptin, and aprotinin; Sigma  Chem- 
ical Co.), followed by a 20-min spin at 12,000 g to remove nuclei 
and membrane fragments. The lysates were precleared with goat 
IgG-Sepharose, immunoprecipitated with Sepharose-coupled  goat 
anti-human/~, washed, separated  by SDS-PAGE, and blotted onto 
PVDF membranes. The blots were then probed with either alka- 
line phosphatase anti-human/~ or anti-Igc~ or anticalnexin  antisera 
in the presence of  3 % BSA. Alkaline  phosphatase-conjugated goat 
anti-rabbit IgG (Southern Biotechnology Associates) was used as 
a secondary antibody where necessary and blots were developed 
by an alkaline  phosphatase  reagent system  (Vector  Labs, Inc., Burlin- 
game, CA). To examine the association of Igcr with transfected 
/x, the anti-IgM immunoprecipitated proteins were divided into 
two aliquots and electrophoresed  separately. One aliquot was probed 
for/x heavy chain and the other for Igor. 
Pulse-Clutse Analysis.  50-100 x  106 cells were initially incu- 
bated in methionine and cysteine-free  medium with 5% dialyzed 
FCS (pulse medium) for 30 min, pelleted, and resuspended in 
fresh warmed pulse medium with 1 mCi 3sS-Express label (NEN, 
Boston, MA) for 5-15 min at 37~  An aliquot of 10-20  x  106 
cells for time 0 was collected, and the remaining cells  were washed 
and resuspended  in complete medium supplemented with methio- 
nine for the chase times indicated. At each time point, 10-20  x 
106 cells were washed, lysed, precleared, immunoprecipitated  with 
anti-# antibody as above, and analyzed by 8% SDS-PAGE. Gels 
were run until the 21-kD marker had reached the bottom to op- 
timize separation at 50-100 kD. To determine the proportion of 
labeled/~ that was bound to calnexin after chase, lysates  from each 
time point were sequentially  immunoprecipitated  with anticalnexin 
antiserum followed by anti-mouse K. This allowed separation of 
# heavy chain that was bound to calnexin from heavy  chain that 
had been released from calnexin, processed, and complexed with 
light chain. The amount of heavy chain in each immunoprecipi- 
tate was quantified  by Phosphorlmager (Molecular  Dynamics, Inc., 
Sunnyvale, CA) analysis  of 10% SDS-PAGE gels, and the amount 
of transfected ~ heavy chain bound to calnexin was expressed as 
a percentage of the total heavy chain immunoprecipitated (bound 
plus released). For endoglycosidase  H (Endo-H) analysis,  cells  were 
pulsed  with  [3SS]methionine for  15  rain  and  chased in  sup- 
plemented complete medium as above. Cell aliquots were lysed at 
each time point and immunoprecipitated  with anti-/~ antibody.  The 
proteins coupled to beads were solubilized, divided into two ali- 
quots, and treated with Endo-H or left untreated. The treated and 
untreated aliquots were then analyzed by 8% SDS-PAGE. 
Analysis oflntracelhlar  Ca 2+ Flux.  2  x  106 cells were loaded 
for 30 min at 37~  with 5/~g/ml Fura-2 (Sigma Chemical Co.). 
They were then washed and resuspended in balanced salt solution 
containing 1.8 mM CaC12, placed in cuvettes, and allowed  to equil- 
ibrate in a fluorimeter (model LS 5B; Perkin Elmer-Cetus Corp., 
Norwalk, CT) at 370C until baselines were established. Excitation 
occurred at 339 nm and emission was measured at 510 nm. Anti- 
body or antigen was added and the fluorimetric response was mea- 
sured. Triton X-100 (Sigma Chemical Co.) was added to 1% to 
establish a maximum signal, followed  by EGTA to 100 mM to es- 
tablish a minimum. 
Results 
Expression  of Transfected Ig in J558L  Cells.  To study the 
role of Igo~ in cell surface expression of the BCR, we cotrans- 
162  Control  of IgM Surface Expression Figure  1.  Surface  expression of transfected WT and mutant IgM in 
cloned  J558L transfectants.  Cells  were  labeled  with FITC-conjugated  goat 
gamma globulin  as a control  (o~n curve) or with FITC-conjugated  anti- 
human IgM (shaded  curve). Plots  indicate  cell number  vs. log fluorescence 
intensity. 
fected WT, YS:VV and Y:F constructs with K light chains 
into the mouse plasmacytoma line J558L, which is Igcx nega- 
tive but expresses Ig/3. Fig. 1 shows the results of flow cyto- 
metric analysis of J558L transfectants stained with FITC- 
anti-human/~. The WT transfectant of J558L retained the 
transfected mlgM intracellularly, expressing little or no mlgM 
on the cell surface. This result, using other # constructs, has 
been reported previously and is the basis of the conclusion 
that Igc~  plays a key role in controlling BCP, expression (22). 
In striking contrast to the WT construct, the YS:VV mu- 
tant was expressed on the plasma membrane at very high levels. 
The Y:F mutant, which associates with IgoL in A20 cells in 
Figure  2.  Expression  of transfected  t* and Ig~x  in J558L transfectants. 
J558L WT, YS:W, and Y:F transfectants,  as well  as an A20 WT transfec- 
tant, were lysed,  immunoprecipitated  with anti-human #, and the im- 
munopreeipitates  split into two aliquots, followed  by separation  by SDS- 
PAGE  and transfer  to membranes. (,4) Expression  of  transfected  IgM. Trans- 
ferred/z proteins were visualized  with alkaline  phosphatase-conjugated 
anti-human IgM. Both  cytoplasmic  and plasma membrane  forms  of IgM 
are detected  by this assay. A single  band is seen in J558L WT and J558L 
Y:F and doublets  seen  in A20 WT and  J558L  YS:VV, indicated  by arrows. 
(B) Expression of/,-associated Igcx in A20 and J558L transfectants  de- 
tected with rabbit antipeptide antiserum to Ig~x. Igo~  is not present in 
any of the J558L transfectants. 
the same manner as the WT mlg (11), was also retained in- 
tracellularly comparable to WT, providing a useful control 
for the nonspecific effects of changes within the # transmem- 
brahe region. These results are representative of multiple clones 
obtained from bulk populations of transfectants by limiting 
dilution. Transfected cells grown in selection medium with 
G418 but not subjected  to limiting dilution or selection on 
the basis of surface Ig expression (the bulk populations) were 
also analyzed, yielding similar results.  20 of 20 J558L WT 
and 18 of 18 J558L Y:F clones and the bulk population from 
each transfection showed little or no IgM on the surface. 20 
of 21 clones of J558L YS:VV  transfectants, as well as the 
original bulk population,  showed very high expression  of 
mlgM by flow cytometric analysis. 
To demonstrate that transfectants that failed to express sur- 
face IgM did synthesize the protein, cells were lysed in 1% 
DM  in lysis medium and immunoprecipitated with anti- 
human IgM coupled to Sepharose beads.  The immunopre- 
cipitated proteins were split into two aliquots, separated by 
SDS-PAGE, and transferred to membranes for immunoblot 
analysis of/~ heavy chain as well as associated Ig~x (see below). 
Fig.  2 A  shows that both WT, YS:W and Y:F  #  heavy 
chains were synthesized in J558L cells at levels comparable 
to A20 transfectants. Therefore, the failure of  J558L cells to 
express  the WT/~ is not due to  the lack of synthesis of 
the transfected Ig. These analyses  revealed an interesting differ- 
ence between the constructs.  In the two transfectants in which 
IgM is expressed on the cell surface, i.e., A20 WT andJ558L 
YS:VV, the heavy chain was seen as a broad band suggestive 
of a doublet, whereas in the case of the intracellularly re- 
tained J558L WT or J558L Y:F, only a narrow, single band 
was seen. This suggests differential processing of the mutant 
and WT #  in the J558L transfectants, a difference that cor- 
responds to whether the molecule is expressed on the sur- 
face or not. 
A20  J558L 
WT  YS:VV 
T 
2~  T 
,  ,i 
Figure  3.  Ca  2+ flux  measured  upon mlg cross-linking.  A20 WT and 
J558L YS:W cells  were  labeled  with Fura-2 and assayed  for induced  Ca  2+ 
flux upon anti-IgM cross-linking. After equilibration, 50 #g/ml goat 
anti-human IgM was added to the cells (arrows) and changes in intracel- 
lular Ca  2+ were measured. Fluorescence  intensity  is measured  over time. 
163  Grupp  et al. Figure 4.  Processing of# heavy chains inJ558L calls. (A) Pulse-chase 
analysis. J558L  WT and J558L  YS:VV cells were labded with [3sS]me- 
thionine, chased for the time indicated (rain) with chase medium, and # 
heavy chains were analyzed by immunoprecipitation and SDS-PAGE. Gels 
were imaged with a Phosphorlmager.  (B) Glycosylation of # heavy chains. 
Calls were labeled and then chased for 0 min (]5581. YS:VV) and 150 
min (J558L WT andJ558L YS:VV), followed by lysis in 1% NP-40. The 
lysates were immunoprecipitated with anti-human IgM and then treated 
with (+) or without (-) Endo-H, TCA precipitated, and separated by 
8%  SDS-PAGE. 
It is formally possible that the J558L YS.'VV transfectants 
are revertants that express Igcz (22) and that this is respon- 
sible for surface expression of the transfected, mutant IgM. 
To demonstrate that  no J558L  transfectant  expressed Igcx 
inappropriately, aliquots of  immunoprecipitated  # and #-as- 
sociated proteins were probed for Ig~x expression by immu- 
noblot using an anti-Igcz antiserum.  As shown in Fig. 2 B, 
no #-associated Igo~ was detectable in any J558L line. The 
WT transfectant of the Igcz-expressing line A20 was used 
as a positive control and showed expression of Igcz. A second 
approach for assessing the integrity of the BCR complex in 
J558L cells was based on previous work with A20 transfec- 
tants, showing that association with IgoL  is required for mlg 
to transduce ligand-induced  signals, such as an increase in 
intracellular Ca  2+ (11, 12). Thus, we tested J558L YS:W for 
the ability to trigger a calcium flux upon cross-linking with 
anti-/~ antibody. Fura-2-1abeled A20 WT and J558L YS:VV 
cells were treated with 50/~g/ml anti-/~ and changes in intra- 
cellular calcium were assayed  with a spectrofluorimeter. This 
concentration of antibody induced an increase in intracellular 
calcium in A20 WT, but no such signal was seen in J558L 
YS:VV (Fig. 3). Therefore, both biochemical and functional 
assays establish that the YS:VV mutant is expressed on the 
surface of J558L cells in the absence of Igor. 
Intracellular Processing of Transfected /~ in J558L.  To fur- 
ther characterize differences in the intracellular processing of 
the retained WT and the expressed mutant Ig YS:VV and 
define the site(s) of  retention of the WT/~ in the  J558L cells, 
we used a pulse-chase technique. In these experiments, cells 
were metabolically labeled for a 15-min pulse, followed by 
a chase for 0~  rain in methionine-supplemented  chase 
medium. In this way, it is possible to follow the cohort of 
Ig molecules that is synthesized during the short pulse period, 
looking for changes in apparent molecular weights indica- 
tive of processing and glycosylation. After the chase, cells 
were lysed and IgM immunoprecipitated,  followed by SDS- 
PAGE under conditions designed to emphasize separation in 
the 50-100-kD range. As seen in Hg. 4 A, a higher Mr form 
of YS:VV IgM appeared by 150 min, consistent with pro- 
cessing on the way to the plasma membrane. This processing 
did not take place in the case  of the WT IgM, in which the 
higher Mr form did not appear. In both cases, there was a 
core, glycosylated  form, the presence  of  which decreased  slowly 
over time, as well as a smaller form which may represent un- 
glycosylated  peptide that decreased  much more quickly (within 
30-60 min). The pattern of processing of the WT/~ sug- 
gests that this protein is retained in the ER. 
To further define the possible site of  intracellular retention 
of WT IgM, the pulse-chase  strategy was used,  foUowed 
by treatment of the immunoprecipitates with Endo-H. The 
glycosylation of  ER resident proteins is typically Endo-H sen- 
sitive, whereas passage through the Golgi stack matures the 
sugar residues and renders the molecule Endo-H resistant. 
Fig. 4 B shows Endo-H analysis  of WT and mutant Ig mole- 
cules in J558L transfectants. Directly after a 15-min pulse, 
almost all of the YS:VV/~ was Endo-H sensitive, consistent 
with ER localization. After a chase of 150 min, a large frac- 
tion of the YS:VV material became Endo-H resistant, indi- 
cating movement out of the ER and through the Golgi. This 
contrasts with WT, which remained entirely Endo-H sensi- 
Figure 5.  Association of calnexin with transfected/~.  Cells were lysed 
with 1% DM lysis medium (DM) or I% NP-40 lysis medium (NP) and 
lysates  immunoprecipitated with anti-IgM Sepharose beads. DM beads were 
washed with DM lysis medium and NP beads were washed with a high 
stringency wash buffer containing 1% NP-40, 0.1% SDS, and 0.1% deox- 
ycholate in Tris-saline. Proteins  were separated by 10%  SDS-PAGE fol- 
lowed by immunoblotting with an anticalnexin  antiserum. No calnexin 
was detected  after immunoprecipitation of cell lysates with preimmune 
goat lgG (not shown). 
164  Control of IgM Surface Expression tive even at 150 min. Again, this indicates that the WT mol- 
ecule has been retained  within  the ER. 
Role of  Calnexin in Intracellular  Retention of  ~ Heavy Chains. 
Given the EK retention of the WT IgM, it was important 
to look for a possible retention or chaperone molecule. One 
recently described candidate is calnexin (IP90, P88; 23, 24), 
a 90-kD molecule that is involved in EK retention of mono- 
meric proteins until  they reach their  mature  configuration 
(25).  There is also evidence that  calnexin may be involved 
in the ER retention of multirneric complexes, mediating reten- 
tion until all members of the complex have been assembled 
(21,  23,  26).  With  this in mind,  we used an antiserum  to 
calnexin to probe for calnexin association with both the WT 
and mutant  (YS:W)  #.  Since the mutant  is released from 
the EK, we hypothesized that  this release was on the basis 
of failure of the mutant  #  to bind  calnexin.  Fig.  5  shows 
that this was not the case. Immunoblot analysis  of calnexin 
associated with WT and YS:W # heavy chain demonstrated 
that  at least some of the #  molecules in each case were as- 
sociated with calnexin.  This was true both under more strin- 
gent and relatively less stringent  lysis and wash conditions; 
i.e.,  in cells that were lysed with  1% NP-40 or the weaker 
nonionic  detergent  DM. 
It was possible that although both mutant and WT # bound 
to calnexin initially,  the kinetics of release  from calnexin of 
each molecule was different. To test this, we used pulse-chase 
labeling followed by sequential immunoprecipitation, first with 
anticalnexin  antiserum  to isolate #  protein associated with 
calnexin,  and then with anti-mouse t~ to separate heavy chain 
that had been released from calnexin and assembled with the 
transfected  light  chain.  Fig.  6  shows  that  essentially  all 
(>90%)  of the WT  #  chain  was bound to calnexin  at  all 
time points examined.  By contrast,  the mutant  #  (YS:VV) 
was released from calnexin over time,  with  78%  of the # 
bound at time 0 and only 33% bound by 3 h. Fig. 6 shows 
the  result  from  one experiment;  in  a  second  experiment, 
>93%  of the WT #  was calnexin associated at both 0 and 
3 h,  whereas 80% of the YS:VV #  was calnexin  associated 
at  time 0  and 48%  by 3  h. 
Role of Igat in  the Release of /~ Heavy  Chains from  Cal- 
nexin.  If the failure of the WT #  chain to be released from 
calnexin is indeed due to the absence of Igor, then coexpressing 
Igc~ should lead to release of #  and surface expression of the 
BCK. To formally test this, we transfected J558L WT cells 
with Igor.  Fig. 7 A  shows flow cytometric analysis of  J558L 
WT and J558L WT/Igot cells demonstrating that in J558L 
WT/Igc~ double transfectants mlgM was expressed at levels 
equivalent to J558L YS:VV. To examine the release of# from 
calnexin,  J558L  WT/Igot  transfectants  were  pulsed  with 
[3SS]methionine  for 5 min, chased for 3 h,  and the #  heavy 
chain both bound to and released from calnexin was analyzed 
by SDS-PAGE. As shown in Fig.  7 B, after 3 h  of chase,  in 
the J558L WT cells all the #  remained calnexin associated, 
whereas  in  the  J558L  WT/Igc~  double  transfectants  a 
significant fraction of the #  protein was released.  Quantita- 
tion of the autoradiogram  shown in  Fig.  7 B revealed that 
100% of the # was calnexin bound in J558L WT cells, whereas 
36% of the total #  protein was released over the same time 
in J558L WT/Igot cells.  Thus, coexpression of Igor releases 
the WT  #  protein  from calnexin  and permits  it  to be ex- 
pressed on the cell  surface. 
Discuxion 
The expression of Ig in B cell lines provides a model for 
analyzing the control of surface expression and function of 
integral membrane protein receptor complexes. We have used 
WT and mutant Ig molecules to characterize the importance 
of the TM region in mediating two key aspects of the mole- 
Figure  6.  Release  of# from calnexin over  time. (A) Cells  were  labeled 
with [3sS]methionine  for 5 min followed  by a chase for the time indicated. 
DM lysates  were sequentially  immunoprecipitated with anticalnexin an- 
tiserum and anti-K, separating heavy  chain bound to calnexin (B) from 
released heavy  chain (R). IgM heavy  chain is indicated (a), as well as a 
band migrating at the correct Mr to be calnexin. (/3) Total incorporation 
was measured  using the PhosphorImager and the amount of immunopre- 
cipitated heavy  chain bound to calnexin was expressed  as a percent of the 
total immunoprecipitated # heavy chain. 
165  Grupp  et al. Figure 7.  Effect  of Ig on calnexin release  and surface  expression of WT mlgM. (.4) Flow cytometric analysis  of mlgM in J558L transfectants: from 
left to right, control (]558L WT cells stained with FITC-goat gamma globulin), J558L WT (stained with FITC-GAH#), and J558L WT/Ig~ (FITC- 
GAH/~). (B) Release of transfected/~ from calnexin. J558L WT and J558L WT/Igc~ transfectants were labeled with [3sS]methionine,  chased for 3 h, 
and lysates sequentially immunoprecipitated as in Fig. 6. The/~ bound to calnexin (B) and released (R) after 3 h are shown. 
cule's behavior.  Previously, we have shown that the TM re- 
gion mediates association with other molecules of the BCR 
complex, and thus the signaling capability of the complex. 
In this study we show that the TM region also determines 
the surface expression of mlgM. Specifically,  the polar residues 
in the WT TM sequence that are involved in noncovalent 
association  with Igor and Ig/3 also confer on mlgM the re- 
quirement for complex assembly before the molecule can be 
expressed on the cell surface. In the absence of assembly of 
the complex, synthesized WT mlgM is retained in the ER. 
A nonconservative dipeptide substitution in the TM region 
completely changes the behavior of mlgM. This mutant is 
expressed at high levels on the cell surface without the re- 
quirement of complex assembly. Further, our data suggest 
that association with and release from calnexin are key deter- 
minants of surface expression of IgM. When Igor is provided 
to complete assembly of the complex, WT IgM is released 
from calnexin and expressed on the cell surface. 
Previous studies from other laboratories  have also impli- 
cated the TM region of # in intracellular retention (27), but 
the constructs used differ  significantly from  ours in  two 
respects. First, Williams et al. (27) used murine/x constructs, 
whereas we have used human C/z because its expression can 
be followed unambiguously, and hybrids between transfected 
and endogenous Ig heavy chains are not seen (13). It should 
be noted that the TM regions of human and mouse/~ differ 
only in a single nonpolar residue  at position 572.  Second, 
Williams et al. (27) concluded that the NH2-terminal polar 
patch of the TM region (TTAST, beginning at residue 572) 
is involved in retention, using a construct with many more 
TM residues altered than those employed  in our studies. Our 
data, however, indicate that the COOH-proximal polar re- 
gion (YSTTVT, beginning at residue 587) is key, both in 
controlling association with Igor and Ig/3 and in controlling 
specific intracellular retention. Our analysis of a nonconser- 
vative dipeptide mutation in the TTAST region (TTAST to 
TTAVV) demonstrates intact signaling and binding to Igoz 
and Ig/3 (11). The reasons for the differences in our results 
and those of Williams et al. (27) are not clear, but may relate 
to the use of different  constructs. 
The striking expression of mlgM in the absence of associated 
Igor inJ558L cells has given us a tool for studying how sur- 
face expression of this protein is controlled. Calnexin has been 
implicated in the EtL retention of immature proteins as they 
are prepared for secretion or surface expression. Monomeric 
proteins are bound to calnexin during or soon after synthesis 
and then released when correctly processed and folded (25), 
whereas misfolded or aberrantly glycosylated proteins are not 
released.  More recently,  calnexin  association  has also been 
demonstrated as a potential control mechanism for multi- 
meric complex assembly, for both MHC class I (28) and the 
TCR-CD3 complex (26).  In these cases, it is hypothesized 
that single chains of a multimeric complex are retained in 
the ER by calnexin until all molecules of the complex are 
assembled,  at which time the complex is released for trans- 
port to the Golgi and on to the surface. The studies described 
here support a similar role for calnexin in the expression of 
the BCR complex. Thus, we postulate that newly synthe- 
sized WT/z heavy chains are bound to calnexin and retained 
in the ER (Fig. 8). In this model, Igor, possibly associated 
with Ig/3, releases/z from its calnexin-binding site, allowing 
subsequent processing and surface expression. In the absence 
of Igtx, as in the J558L transfectants,  the WT/z remains cal- 
nexin bound. In contrast, the YS:W mutant binds only tran- 
siently to calnexin and is spontaneously released without the 
requirement for Igor, resulting in surface expression. Cotrans- 
fection of WT # and Igc~ formally shows that Igor is required 
for the release of the/z heavy chain from calnexin. Note that 
the YS:VV mutation does not abolish the association between 
calnexin and the/~ protein, since the mutant transiently binds 
to calnexin. 
Given the wide variety of proteins that calnexin chaperones, 
it seems impossible that there is any consensus sequence motif 
for calnexin binding. Rather, it is more likely that binding 
to calnexin is mediated by carbohydrate moieties. This is con- 
sistent with the release of monomers as they achieve mature 
conformation and glycosylation. The YS:W mutation may 
alter the glycosylation of the/z chain, thereby reducing the 
avidity of its association with calnexin and allowing "spon- 
taneous" release from the chaperone.  In WT  #  proteins, 
calnexin-binding carbohydrate moieties may only be detached 
from calnexin by the binding of the BCR complex compo- 
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Figure 8.  Model  for the control of 
mlg  expression. In  mature, Igol- 
expressing B cells (represented  by the 
lymphoma  line A20), IgM is retained 
in the EIL until the BCR complex is 
assembled, including Igol. When the 
complex  is assembled, IgM is released 
for expression on the cell surface. In 
differentiated B cells that no longer 
express Igcr (represented  by the plas- 
macytoma lineJ558L), WT IgM is 
retained in the EIL by cahaexin over 
time. Expression  is restored  by trans- 
fection of  J558L with Igoe. The mu- 
tant YS:W, on the other hand, does 
not require assembly  with Igoe  for re- 
lease to the surface. 
nent Igce (with or without Igl3). The mutation in the BCR 
retention signal described here changes the mutant BCR from 
a processing pathway appropriate  to a multicomponent re- 
ceptor complex, mandating retention until the whole of the 
complex is assembled, to a processing pathway requiring only 
proper folding, glycosylation and, possibly,/zg association. 
These studies with Ig transfectants have broad implications 
for the assembly and expression of multimeric protein receptor 
comple~s. An important function of associated proteins, such 
as Igcx and Igfl for the BCR, may be to release newly syn- 
thesized receptors from intracellular retention sites. Develop- 
mentally regulated expression of associated proteins will, there- 
fore, control intracellular retention vs. surface expression of 
the complexes, allowing expression during maturational stages 
at which the receptors are required for function. 
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